The economist thinks the Fed ought to pay more attention to financial markets when setting interest rates.The Fedread more
U.S. President Donald Trump's latest tariff increase — and Beijing's plans to counter them — are hitting U.S. companies in China, according to a joint survey this month by...China Economyread more
"We are also constantly watching whether the trade war will turn into a tech war," Ma said Tuesday, according to a CNBC translation of his Chinese remarks published by a locak...China Economyread more
Kohl's, J.C. Penney and Nordstrom release disappointing earnings news, putting a damper on their sector.Retailread more
Bezos's comments give a rare glimpse into his interest in the auto industry. Amazon recently invested in two self-driving start-ups.Technologyread more
While investing often seems like a contrarian game where going against the flow feels like the better bet, the reality is that investors who bought the most-favored stocks...Hedge Fundsread more
Talks between the world's two largest economies have stalled after each nation lobbied higher tariffs on the other's imports.Traderead more
"Pretty much the entire suite of apps that 'talk' over the internet could be vulnerable," said Tom Uren, a senior analyst at the Australian Strategic Policy Institute's...Cybersecurityread more
A Chinese official in Hong Kong is urging the quick passage of legal measures to allow fugitives to be transferred to the mainland.China Politicsread more
GAC Motor said its delaying its launch in the U.S. but had no timeline when it could launch there.Autosread more
The U.S. administration is considering limits to Chinese video surveillance firm Hikvision's ability to buy U.S. technology, the New York Times reported on Tuesday, deepening...World Politicsread more
ASCO, the world's largest cancer research conference, starts Friday in Chicago, where oncologists, investors and pharmaceutical executives converge to discuss the latest advancements in treatment.
Immunotherapies, medicines that enable the immune system to better fight cancer, will continue to be a top focus of the conference. Merck, Bristol-Myers, Roche, AstraZeneca, Pfizer and others are working in the space, which BMO Capital Markets analyst Alex Arfaei estimates may be worth $30 billion by 2020. The cost to treat cancer is sure also to be a major topic.
But it's the smaller companies that often see the biggest stock moves out of ASCO (which stands for the American Society of Clinical Oncology). Already the Nasdaq Biotech Index has rallied into the conference, gaining 6 percent in the last five days. Yet many analysts say this year's meeting looks to be a slower one from an investment perspective. So we decided to ask Kensho, a market data analytics system, what history tells us to expect from ASCO stock performance.
Looking at ASCO meetings since 2011, and a lengthy list of presenting companies with market values of at least $1 billion from a JPMorgan research note, here's what we found:
The most consistently positive performers out of ASCO are Seattle Genetics, Regeneron, Ariad, Ionis Pharmaceuticals and Halozyme Therapeutics, which traded up at least four years out of the last five (or 80 percent of the time). That's if investors bought the stock the first day of the conference and sold a week afterwards.
Some of those companies will be closely watched at this year's conference as well: Ariad, for new data on its experimental lung cancer drug, brigatinib, and Seattle Genetics, both for data from a competitor in Hodgkin's lymphoma and for one of its internal programs in urothelial cancer, according to RBC Capital Markets.
Another way to track stock performance out of ASCO is a relatively new exchange-traded fund focused exclusively on companies working in immunotherapy, the CNCR Immunotherapy ETF. Started by investor Brad Loncar, it's also rallied into the conference, returning more than 13 percent since initial datasets were released ahead of the conference May 18.
(Source: Loncar Investments. Data as of Thursday's close.)
As for biotech stocks more broadly, Kensho tells us the IBB, the ETF that tracks the Nasdaq Biotech Index, historically only slightly outperforms the broader market through ASCO, returning an average of 0.64 percent from the first day of the conference to a week later, versus 0.56 percent for the S&P 500.
Disclosure: NBCUniversal, parent of CNBC, is aminority investor in Kensho.